TABLE 5.
Subgroup analyses of BUN based on treatment duration, baseline of 24h-UTP, baseline of Scr and type of RASI.
| Criteria for grouping | Subgroups | n | MD (95%CI) | I2(%) | Z | P |
|---|---|---|---|---|---|---|
| Treatment duration | 8 weeks | 10 | −0.44(−0.82, −0.06) | 74 | 2.26 | 0.02 |
| 12 weeks | 7 | −0.38(−0.97, 0.20) | 87 | 1.28 | 0.20 | |
| ≥16 weeks | 2 | −1.88(−5.32, 1.56) | 99 | 1.07 | 0.28 | |
| Baseline of 24h-UTP | <1 g | 1 | −0.69(−1.10, −0.28) | - | 3.31 | 0.0009 |
| 1–2 g | 5 | 0.11(−0.13, 0.35) | 0 | 0.91 | 0.36 | |
| >2 g | 5 | −0.94(−1.98, 0.10) | 89 | 1.77 | 0.08 | |
| Baseline of Scr | <90 μmol/L | 7 | −0.09(−0.41, 0.23) | 66 | 0.56 | 0.58 |
| 90–110 μmol/L | 4 | −0.18 (−0.58, 0.22) | 61 | 0.87 | 0.39 | |
| 110–133 μmol/L | 5 | −0.50 (−1.13, 0.13) | 72 | 1.57 | 0.12 | |
| Type of RASI | ACEI | 6 | −0.77 (−1.59, 0.05) | 87 | 1.84 | 0.07 |
| ARB | 13 | −0.52 (−1.11, 0.07) | 94 | 1.72 | 0.09 |
RASI, Renin-angiotensin-aldosterone system inhibitor; ACEI, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin-receptor blocker; 24h-UTP, 24h-urine total protein; Scr, Serum creatinine.